Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVS’ Longs offer questioned

This article was originally published in The Tan Sheet

Executive Summary

CtW Investment Group urges Longs Drug Stores Corp., which CVS recently moved to purchase, to disclose the full value of its real estate portfolio through an independent third-party appraisal so Longs' shareholders can "make a fully informed decision" about CVS' offer (1"The Tan Sheet" Aug. 18, 2008, p. 19). Meanwhile, Longs' board has declined to consider a competing offer from Walgreens. CtW believes CVS' tender offer "undervalues the company's real estate assets" by between 18 and 26 percent, according to a Sept. 2 letter to Longs. The group says it is "disturbed by the news that Longs entered into a previously undisclosed agreement with CVS/Caremark not to reveal the value of its real estate portfolio.

You may also be interested in...



Walgreens drops Longs bid

Walgreens withdraws its proposed purchase of all outstanding shares of Longs Drug Stores Corp. in light of the Longs' board's decision to accept the tender offer made by CVS/Caremark, Walgreens CEO Jeffrey A. Rein says in an Oct. 8 letter. Walgreens' offer of $75 per share was rejected by Longs in September (1"The Tan Sheet" Sept 22, 2008, In Brief). Rein announced Oct. 10 he was leaving after 26 years with the company, effective immediately. The Deerfield, Ill.-based company named Alan G. McNally, lead director of its board, as chairman and acting CEO

CVS Stretches California Footprint, Reaches Hawaii With Longs Buy

CVS/Caremark is gaining a retail pharmacy presence in major new markets in California and other western states through its acquisition of Longs

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Topics

UsernamePublicRestriction

Register

PS102117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel